Evidence map›Paper›PMID 26519476›Full record

ArticleJournal of cell science2015

Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells.

Robert L Satcher, Tianhong Pan, Mehmet A Bilen, Xiaoxia Li, Yu-Chen Lee, Angelica Ortiz, Andrew P Kowalczyk, Li-Yuan Yu-Lee, Sue-Hwa Lin

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. From Neural Crest Development to Cancer and Vice Versa: How p75Frontiers in molecular neuroscience · 2018
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Robert L SatcherDepartment of Orthopedic Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Tianhong PanDepartment of Orthopedic Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Mehmet A BilenDepartment of Translational Molecular Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaoxia LiDepartment of Translational Molecular Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Yu-Chen LeeDepartment of Translational Molecular Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Angelica OrtizDepartment of Translational Molecular Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Andrew P KowalczykDepartment of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Li-Yuan Yu-LeeDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Sue-Hwa LinDepartment of Translational Molecular Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA slin@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USEmory University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J., THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Endothelial-to-osteoblast transition in prostate cancer bone metastasisR01CA174798 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, SUE-HWA · 2013 to 2023
$3.0M
NCI NIH HHS CA16672NCI NIH HHS CA174798NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA174798
6 · The paper itself

Abstract

Cadherin-11 (Cad11) cell adhesion molecule plays a role in prostate cancer cell migration. Because disassembly of adhesion complexes through endocytosis of adhesion proteins has been shown to play a role in cell migration, we examined whether Cad11 endocytosis plays a role in Cad11-mediated migration. The mechanism by which Cad11 is internalized is unknown. Using a GST pulldown assay, we found that clathrin binds to the Cad11 cytoplasmic domain but not to that of E-cadherin. Using deletion analysis, we identified a unique sequence motif, VFEEE, in the Cad11 membrane proximal region (amino acid residues 11-15) that binds to clathrin. Endocytosis assays using K(+)-depletion buffer showed that Cad11 internalization is clathrin dependent. Proximity ligation assays showed that Cad11 colocalizes with clathrin, and immunofluorescence assays showed that Cad11 localizes in vesicles that stain for the early endosomal marker Rab5. Deletion of the VFEEE sequence from the Cad11 cytoplasmic domain (Cad11-cla-Δ5) leads to inhibition of Cad11 internalization and reduces Cad11-mediated cell migration in C4-2B and PC3-mm2 prostate cancer cells. These observations suggest that clathrin-mediated internalization of Cad11 regulates surface trafficking of Cad11 and that dynamic turnover of Cad11 regulates the migratory function of Cad11 in prostate cancer cells.

Indexed as

Cell MovementEndocytosisCadherinsCell Line, TumorClathrinHEK293 CellsHumansMaleNeoplasm ProteinsProstatic NeoplasmsProtein BindingCadherinsClathrinNeoplasm Proteinsosteoblast cadherinCadherin-11ClathrinEndocytosisMigrationProstate cancer

Identifiers

PMID26519476
PMCPMC4696499
OpenAlexW2308298496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.